Category: Guest content

Biosimilar Naming: Distinguishable or Disingenuous?

This is a guest post from Robert Yapundich, MD and Gregory Schimizzi, MD. Dr. Yapundich is a practicing neurologist in Hickory, North Carolina and a member of the Alliance for Patient Access. Dr Schimizzi is a practicing rheumatologist, treasurer of the Coalition of State Rheumatology Organizations and co-convener of the Biologics Prescribers Collaborative. Distinguishable biosimilar naming was the top issue for […]


Click here for reuse options!
Copyright 2016 Biotechblog

Mainstreaming the Microbiome

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. Towards the end of 2015, I wrote about growing recognition of the importance of the microbiome for human health and consequently for commercial biopharmaceutical development here.  Still microbiome research […]


Click here for reuse options!
Copyright 2016 Biotechblog

Lean, Mean, Startup, Machine

This paper is a final project from the NIH Foundation for Advanced Education in the Sciences course — TECH 566: Biotechnology Management Starting up a company is a risky endeavor. From listening to the FAES 566’s course panel discussions this semester, it is clear that there are many challenges a Chief Executive Officer (CEO) will face […]


Click here for reuse options!
Copyright 2015 Biotechblog

Biotechnology in Countries Beginning with “I” – Part 9: Iran

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. Looking beyond the landmark nuclear deal, Iranian media sources are trumpeting the Islamic State’s prowess in biotechnology.  So how does Iran really measure up – globally and compared to […]


Click here for reuse options!
Copyright 2015 Biotechblog

The Paradox of Pharmaceutical Hyperconnectivity

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. As we head into the dog days of summer I continue to reflect on the  recent DIA and BIO annual meetings held in mid-June. At both events I was […]


Click here for reuse options!
Copyright 2015 Biotechblog

Adventures in Binational Biopharma: Innovative Medicines “Made in India”

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. As a Non-NRI, I did not plan to launch a bio-pharmaceutical start-up company in India on my own. That would be a little crazy. Instead I took a […]


Click here for reuse options!
Copyright 2015 Biotechblog

Cancer's Science Revolution Comes on Little Cat Feet

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. Back when I wrote ISO A Scientific Revolution in Cancer Research in April of 2013, I truly did not expect to be able to greet the revolution by […]


Click here for reuse options!
Copyright 2015 Biotechblog

Expand Your Cell-Based Protein Manufacturing with Hollow Fiber Bioreactors

This is a guest post from Halina Zakowicz, Marketing Specialist at Biovest International, Inc. Do you have a response to Halina’s post? Respond in the comments section below. Scaling up cell culture production can be a tricky proposition. Generating large amounts of cell-secreted proteins is labor-intensive when utilizing traditional cell culture methods. Quality and yields […]


Click here for reuse options!
Copyright 2015 Biotechblog

Biotechnology in Countries Starting with “I” – Part 7: India

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. For the next chapter in this continuing series, let’s turn back to India and the draft National IPR Policy currently under debate in New Delhi. A great deal […]


Click here for reuse options!
Copyright 2015 Biotechblog

Unlocking the Mystery of Angel Investment

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. In the “Mystery of Capital,” Peruvian economist Hernando de Soto famously writes about the need to convert assets into capital for creation of social and economic value in […]


Click here for reuse options!
Copyright 2014 Biotechblog

%d bloggers like this: